Kolinpharma (nutraceuticals): more medical prescriptions in the 4th trim
Sales of food supplements increased in December (+7% in volume and +11% in value)
Kolinpharma, an innovative SME listed on the Aim segment of the Italian Stock Exchange, in the fourth quarter of 2020 confirmed the positive growth trend of medical prescriptions, equal to n. 130,361, up 2% compared to no. 127,887 prescriptions of 4Q 2019. In terms of values, the growth of 4Q is even higher, marking a + 4% compared to the fourth quarter of 2019. The trend also shows a significant acceleration with the month of December alone which recorded an increase in 7% in terms of volumes and 11% in terms of values compared to December 2019. In particular, the good performances of Xinepa were recorded, representing approximately 20% of total prescriptions (17.5% in 4Q 2019) and Ivuxur which represents 19.6% of total prescriptions (17.3% in 4Q 2019).
As of 31/12/2020 the number of Medical Scientific Representatives (IMS) is equal to n. 51 (n. 58 as of 31/12/2019); in the course of 4Q 2020, on average, no. 55 IMS. As already announced on 4 January 2021, the Company continues to invest in the growth strategy and training of the IMS network with the hiring of 33 new professionals.
Rita Paola Petrelli, President of Kolinpharma, commented: “The data of 4Q 2020 highlight the recovery of the market and the excellent work done by all our collaborators in the second part of this very particular year for the Italian and world economy. We therefore confirm the growth we had already recorded in Q3 and highlight the further acceleration in December compared to 2019. Both trends give us great confidence for the 2021 financial year that we started with the launch of the first DOLATROX HCC medical device and the expansion of the IMS network with the inclusion of 33 new professionals".
EFA News - European Food Agency